Takeda's Zasocitinib Delivers in Phase 3 for Hard-to-Treat Psoriasis
Takeda calls phase 3 results for oral TYK2 inhibitor zasocitinib 'top-notch' in difficult-to-treat psoriasis, positioning a pill against biologics.
Topic
Takeda
Topic
Takeda
Takeda reports zasocitinib superior to deucravacitinib
Takeda says its investigational TYK2 inhibitor zasocitinib beat deucravacitinib on efficacy in a head-to-head claim that could re…